secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001213900-26-001777
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma raises $8.0M in registered direct offering and private placement
--------------------------------------------------------------------------------

- Gross proceeds of $8.0M from sale of 4,063,290 shares, 1,000,000 pre-funded warrants, and 7,594,935 PIPE common warrants.
- Combined unit price of $1.58 per share/warrant; PIPE warrants exercisable at $1.39 for 5 years.
- Net proceeds for general corporate purposes and working capital to advance Phase II trial of EB103.
- Placement agent Aegis Capital Corp. received a 6% cash fee on gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390026001777/0001213900-26-001777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390026001777/ea0271975-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-001777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer